The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma

Cancer

Volumn 116, Issue 9, 2010, Pages 2208-2214

  Cereda, Stefano ^a   Passoni, Paolo ^a   Reni, Michele ^a   Viganò, Maria G ^a   Aldrighetti, Luca ^a   Nicoletti, Roberto ^a   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

5 fluorouracil; Biliary tract cancer; Chemotherapy; Cisplatin; Epirubicin; Gemcitabine; PEFG regimen

Indexed keywords

CISPLATIN; CISPLATINO; EPIRUBICIN; ERYTHROPOIETIN; FARMARUBICINA; FLUOROURACIL; FLUOROURACILE; GEMCITABINE; GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT ADENOCARCINOMA; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER; HAND FOOT SYNDROME; HUMAN; INTRAHEPATIC BILE DUCT; LIVER DISEASE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED;

EID: 77951430103     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24970     Document Type: Article

References (46)

1. De Groen PC, Gores JC, La Russo NF, et al. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378.
2. Glimelius B, Hoffman K, Sjoden PO. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600. (Pubitemid 26285639)
3. Falkson G, Macintyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965-969. (Pubitemid 14069807)
4. Takada T, Kato H, Matsushiro T, et al. Combination of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994;51:396-400. (Pubitemid 24255303)
5. Kajanti M, Phyronen S. Epirubicin-sequential methotrexate-5-fluorouracil- leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol. 1994;17:223-226. (Pubitemid 24160612)
6. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with singleagent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001;19:4089-4091. (Pubitemid 32976699)
7. Davis HL Jr, Ramirez G, Ansfield FJ. Adenocarcinomas of stomach, pancreas, liver, and biliary tract. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer. 1974;33:193-197.
8. Okada S, Ishii H, Nose H, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology. 1994;51:515-517. (Pubitemid 24347034)
9. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24:3069-3073.
10. Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005;41:398-403. (Pubitemid 40187211)
11. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101:578-586. (Pubitemid 38970609)
12. Furuse J, Okusaka T, Boku N, et al. S1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849-855.
13. Androulakis N, Aravantinos G, Syrigos K, et al. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology. 2006;70:280-284. (Pubitemid 44670168)
14. Abu-Alfa GK, Rowinsky EK, Patt YZ, et al. A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol. 2005;28:334-339. (Pubitemid 41099536)
15. Alberts SR, Fishkin PA, Burgart LJ, et al. CPT-11 for bileduct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer. 2002;32:107-114.
16. Taal BG, Audisio RA, Bleiberg H, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study. Ann Oncol. 1993;4:607-609.
17. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896-902. (Pubitemid 46452283)
18. Schulz L, Schalhorn W, Wilmanns W, et al. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells [abstract]. Proc Am Soc Clin Oncol. 1998;17:251a. Abstract 965.
19. Sawada N, Fujimoto-Ouchi K, Ishikawa T, et al. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models [abstract]. Proc Am Assoc Cancer Res. 2002;43:1088. Abstract 5388.
20. Aung TT, Davis MA, Esminger WD, et al. Interaction between gemcitabine and mitomycin C in vitro. Cancer Chemother Pharmacol. 2000;45:38-42.
21. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984;2:1245-1248.
22. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343. (Pubitemid 39295020)
23. Sanz-Altamira P, Ferrante K, Jenkins R, et al. A phase II trial of 5-FU leucovorin and carboplatin in patients with unresectable biliary tree carcinoma. Cancer. 1998;82:2321-2325. (Pubitemid 28283437)
24. Patt YZ, Haasan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon a-2b, doxorubicin, and fluorouracil for biliary tract cancer. Clin Cancer Res. 2001;7:3375-3380.
25. Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors. Eur J Cancer. 1995;31:1594-1598.
26. Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192-1196. (Pubitemid 34960126)
27. Kim TW, Chang HM, Lee JR, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14:1115-1120. (Pubitemid 36950177)
28. Thongprasert S, Napapan S, Charoentum C, et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;6:279-281. (Pubitemid 40309310)
29. Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer. 2002;87:702-704. (Pubitemid 35178744)
30. Knox JJ, Hedley D, Oza A, et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004;15:770-774. (Pubitemid 38714738)
31. Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma. Cancer. 2005;103:111-118.
32. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332-2338. (Pubitemid 46218726)
33. Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or bi-weekley high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol. 2004;15:478-483. (Pubitemid 38444553)
34. Park SH, Park JH, Lee JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006;106:361-365. (Pubitemid 43100445)
35. Morizane C, Okada S, Okusaka T, et al. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology. 2003;64:475-476. (Pubitemid 36682965)
36. Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared with epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92:1650-1654. (Pubitemid 40756474)
37. Lee MA, Woo IS, Kang JH, et al. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2004;130:346-350.
38. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol. 2005;6:369-376.
39. Reni M, Passoni P, Panucci MG, et al. Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol. 2001;19:2679-2686. (Pubitemid 32441373)
40. World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO; 1979.
41. Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990;8:147-159.
42. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630-2639.
43. Reni M, Cereda S, Bonetto E, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;59:361-367. (Pubitemid 46025523)
44. Reni M, Cereda S, Bonetto E, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest. 2007;11:1-5. (Pubitemid 350135737)
45. Reni M, Cereda S, Passoni P, et al. A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma. ASCO Annual Meeting Proceedings, Part I [abstract]. J Clin Oncol. 2007;25(18S). Abstract 4628.
46. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of 2 protocol planned interim analyses in a randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancer receiving ECF. Br J Cancer. 2005;92:1976-1983. (Pubitemid 40897418)